Multifocal Breast Carcinoma
Information
- Disease name
- Multifocal Breast Carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01272037 | Active, not recruiting | Phase 3 | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | January 15, 2011 | October 1, 2032 |
| NCT04481113 | Active, not recruiting | Phase 1 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | June 7, 2021 | December 30, 2025 |
| NCT04457596 | Recruiting | Phase 3 | T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | January 6, 2021 | May 2035 |
| NCT03128619 | Terminated | Phase 1 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | August 2, 2017 | March 31, 2022 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006625